Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Status:
Active, not recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 1/2 study to evaluate the safety of durvalumab (MEDI4736) in
combination with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced
oesophageal cancer (OC) and with neoadjuvant chemo(radio)therapy before surgery in operable
OC. The immunotherapy will be given for a 4-week period before starting the standard
chemo(radio)therapy, continuing durvalumab treatment once the chemotherapy starts. The study
will include 2 phases, a safety run-in Phase 1 (Cohorts A1 and A2) and an expansion Phase 2
(Cohorts B, C, C-FLOT, D).